In Finland’s Lapland district—ranked the world’s top mining jurisdiction—Valkea Resources is making early moves that could prove pivotal. Nestled beside Agnico Eagle’s Kittila mine (Europe’s largest ...

Biotech is back! Regulatory tailwinds, cheaper valuations, and Fed cut hopes are boosting ETFs like XBI and IBB. Is the ...

News archive including articles on Fund Managers, Fund Selection, Asset Allocation, Absolute Return, Offshore Investments, ...

On the sell side, ARK trimmed its holdings in several companies, with the most notable sale being 61,072 shares of SHOPIFY INC (NYSE:SHOP), valued at $10,691,264. This followed a pattern of reducing ...

Making its debut on 06/19/2006, smart beta exchange traded fund First Trust NYSE Arca Biotechnology ETF (FBT) provides investors broad exposure to the Health Care ETFs category of the market. What Are ...

Virtus LifeSci Biotech Clinical Trials ETF BBC is probably on the radar for investors seeking momentum. The fund just hit a 52-week high and moved up 138.3% from its 52-week low price of $13.42/share.

Another major investment by ARK was the acquisition of 385,585 shares of Block Inc (NYSE:XYZ), a financial services and mobile payment company formerly known as Square, with a total value of ...

The buyout of one biotechnology company can sometimes hurt the shares of its competitors, as investors may feel like they picked the wrong merger candidate. But not in the case for those who bought ...

Biopharma has finally begun catching up with the overall stock market, as shares of the top three biopharma exchange traded funds (ETFs) jumped well into double digits over the past six months.

BIB ETF is best suited for high-risk, active investors in the accumulation phase or retirees managing portfolios hands-on.

After years of disappointments, biotech stocks are on an unaccustomed run. The SPDR S&P Biotech ETF, which trades under the ticker XBI, is up around 20% since the start of September, and is ...

After years on the sidelines while investors piled into the next big thing in AI or crypto, biotech is back in focus. The question is whether this rally marks a real recovery or just another ...